Illumina, Inc. $ILMN Shares Purchased by Laurel Wealth Advisors LLC

Laurel Wealth Advisors LLC boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 9,441.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,082 shares of the life sciences company’s stock after purchasing an additional 18,882 shares during the quarter. Laurel Wealth Advisors LLC’s holdings in Illumina were worth $1,821,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Rise Advisors LLC increased its stake in shares of Illumina by 173.6% during the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after buying an additional 224 shares during the period. Parkside Financial Bank & Trust grew its holdings in Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 115 shares in the last quarter. Cullen Frost Bankers Inc. purchased a new stake in shares of Illumina in the 2nd quarter valued at approximately $41,000. NewSquare Capital LLC increased its position in shares of Illumina by 604.9% in the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after purchasing an additional 369 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Illumina by 2,936.8% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock valued at $46,000 after purchasing an additional 558 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling at Illumina

In related news, Director Scott Gottlieb purchased 500 shares of the stock in a transaction that occurred on Monday, November 3rd. The shares were purchased at an average price of $122.13 per share, with a total value of $61,065.00. Following the completion of the acquisition, the director directly owned 12,523 shares in the company, valued at $1,529,433.99. This represents a 4.16% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 2.60% of the company’s stock.

Illumina Stock Performance

Shares of ILMN opened at $129.81 on Friday. The company’s 50 day simple moving average is $107.40 and its 200-day simple moving average is $98.82. The firm has a market cap of $19.83 billion, a PE ratio of 16.43, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $153.06. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the business earned $1.14 EPS. Illumina’s quarterly revenue was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ILMN shares. UBS Group boosted their target price on shares of Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Morgan Stanley upped their price objective on Illumina from $100.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Monday, August 4th. Evercore ISI increased their price objective on Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Barclays boosted their target price on Illumina from $95.00 to $100.00 and gave the stock an “underweight” rating in a research note on Friday, October 31st. Finally, Royal Bank Of Canada set a $124.00 price target on Illumina in a report on Tuesday, September 2nd. Five equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Illumina has an average rating of “Hold” and an average price target of $115.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.